<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242082</url>
  </required_header>
  <id_info>
    <org_study_id>PGLUTPEDF</org_study_id>
    <nct_id>NCT04242082</nct_id>
  </id_info>
  <brief_title>Glucose Trnsporter and PEDF in Psoriasis</brief_title>
  <official_title>Role of Glucose Transporter (GLUT) Genes Expression in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic relapsing cutaneous immune mediated inflammatory disease(IMID). In
      which there are skin lesions characterized by erythema, thickness and scale formation with
      different size from a pinhead to 20 cm in diameter. Prevalence of psoriasis is 2% to 4%
      worldwide. Psoriasis occurs at any age with two peaks: between 15-20 years and between 55-60
      years. Women are presented with psoriasis at younger age than men ,but with less severity.
      lesions usually present on knee, elbow, scalp and sacral region this may be attributed to
      higher traumatic incident .

      Psoriasis vulgaris is the most common type, and accounts 90% of cases. Patients with
      psoriasis vulgaris present with pain, itching and bleeding from skin lesions.

      There are many theories for psoriasis pathogenesis: angiogenesis, decrease in apoptosis of
      keratinocyte, hyperproliferation , alteration of cell to cell adhesion and immune-mediated
      inflammation.

      Patients with immune mediated inflammatory disease (IMID) are susceptible to develop diabetes
      mellitus, metabolic syndrome, hyperlipidemia, and hypertension.A previous study found that
      psoriatic patients are more susceptible to type 2 diabetes compared to control.

      Glucose transporter type 1(GLUT1) is upregulated in psoriatic patient attributed to
      angiogenesis and execessive cell proliferation in those patients .Also expression of GLUT 1
      is found high with hyperglycemia . A study reported that GLUT 1 density in placenta of women
      with gestational diabetes was found to be two folds higher than control.

      Pigment epithelium derived factor (PEDF) has antiangiogenic effect. Topical application of
      PEDF on mouse model of psoriatic disease helps in reduction of skin proliferation and
      angiogenesis.

      GLUT 1 overexpression was found to be associated with decrease in PEDF expression in diabetic
      retinopathy.

      In view of that we will compare the level of GLUT 1 gene in psoriatic patients and psoriatic
      patients with diabetes, as well as healthy control, and detect the effect of PEDF on GLUT 1
      expression in vitro using human keratinocytes cell line .
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GLUT1 expression in psoriatic patients with or without type 2 diabetes.</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>assessing fold changes of GLUT1 expression in blood samples using real time PCR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GLUT1 expression in keratinocyte before and after treatment with pigment epithelium derived factor (PEDF)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>patients with psoriasis vulgaris only</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with psoriasis vulgaris and type 2 diabetes mellitus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GLUT 1 gene expression</intervention_name>
    <description>GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.
Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment.</description>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_label>patients with psoriasis vulgaris and type 2 diabetes mellitus</arm_group_label>
    <arm_group_label>patients with psoriasis vulgaris only</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will taken from three groups.Then RNA will be extracted,then used for cDNA
      formation followed by real time PCR to see fold changes of GLUT1 genes expression.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        first group (N=25) : Patients with psoriasis vulgaris second group(N=25) :Patients with
        psoriasis vulgaris and type 2 diabetes third group(N=25) : healthy control

        data collection :

          -  Sex

          -  Age

          -  BMI

          -  Blood glucose level ,HA1c using high performance liquid chromatography (HPLC)

          -  Duration of disease (T2D and psoriasis)

          -  Severity of psoriasis by psoriasis area severity index (PASI)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with psoriasis vulgaris Patients with psoriasis vulgaris and type 2 diabetes

        Exclusion Criteria:

          -  Factors affect GLUT 1 expression As: tumors either benign or malignant cause increase
             GLUT 1 expression
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naglaa K Idriss, asst. prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayaat ِA Sayed, asst. prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherouk S Elkady, demonstrator</last_name>
    <phone>+002 01066090960</phone>
    <email>sheroukelkady@med.aun.edu.eg</email>
  </overall_contact>
  <link>
    <url>https://www.wjgnet.com/2218-6190/full/v3/i3/36.htm</url>
    <description>Gender medicine and psoriasis doi: 10.5314/wjd.v3.i3.36</description>
  </link>
  <results_reference>
    <citation>Abdou AG, Maraee AH, Eltahmoudy M, El-Aziz RA. Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis. Am J Dermatopathol. 2013 Oct;35(7):731-7. doi: 10.1097/DAD.0b013e3182819da6.</citation>
    <PMID>23392136</PMID>
  </results_reference>
  <results_reference>
    <citation>Sondermann W, Djeudeu Deudjui DA, Körber A, Slomiany U, Brinker TJ, Erbel R, Moebus S. Psoriasis, cardiovascular risk factors and metabolic disorders: sex-specific findings of a population-based study. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):779-786. doi: 10.1111/jdv.16029. Epub 2019 Dec 3.</citation>
    <PMID>31797464</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82. doi: 10.14744/nci.2016.16023. eCollection 2016. Review.</citation>
    <PMID>28058392</PMID>
  </results_reference>
  <results_reference>
    <citation>Holm JG, Thomsen SF. Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019 Jan 17;9:1-6. doi: 10.2147/PTT.S159163. eCollection 2019. Review.</citation>
    <PMID>30697518</PMID>
  </results_reference>
  <results_reference>
    <citation>Granata M, Skarmoutsou E, Trovato C, Rossi GA, Mazzarino MC, D'Amico F. Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. Pathobiology. 2017;84(2):71-79. doi: 10.1159/000447777. Epub 2016 Sep 17. Review.</citation>
    <PMID>27639922</PMID>
  </results_reference>
  <results_reference>
    <citation>Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017 Aug;18(4):583-590. doi: 10.1007/s40257-017-0274-0.</citation>
    <PMID>28342016</PMID>
  </results_reference>
  <results_reference>
    <citation>Li Y, Song Y, Zhu L, Wang X, Yang B, Lu P, Chen Q, Bin L, Deng L. Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo. Clin Cosmet Investig Dermatol. 2019 Nov 29;12:865-873. doi: 10.2147/CCID.S218243. eCollection 2019.</citation>
    <PMID>31819584</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsuura T, Sato M, Nagai K, Sato T, Arito M, Omoteyama K, Suematsu N, Okamoto K, Kato T, Soma Y, Kurokawa MS. Serum peptides as putative modulators of inflammation in psoriasis. J Dermatol Sci. 2017 Jul;87(1):36-49. doi: 10.1016/j.jdermsci.2017.03.014. Epub 2017 Mar 27.</citation>
    <PMID>28431948</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JH, Kim JS, Park SY, Lee YJ. Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1. Oncol Rep. 2016 Jan;35(1):524-9. doi: 10.3892/or.2015.4332. Epub 2015 Oct 16.</citation>
    <PMID>26499368</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaker O, Abdel-Halim M. Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA. Eur J Dermatol. 2012 Mar-Apr;22(2):218-24. doi: 10.1684/ejd.2012.1649.</citation>
    <PMID>22361809</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaither K, Quraishi AN, Illsley NP. Diabetes alters the expression and activity of the human placental GLUT1 glucose transporter. J Clin Endocrinol Metab. 1999 Feb;84(2):695-701.</citation>
    <PMID>10022440</PMID>
  </results_reference>
  <results_reference>
    <citation>Calado SM, Alves LS, Simão S, Silva GA. GLUT1 activity contributes to the impairment of PEDF secretion by the RPE. Mol Vis. 2016 Jul 14;22:761-70. eCollection 2016.</citation>
    <PMID>27440994</PMID>
  </results_reference>
  <results_reference>
    <citation>Abe R, Yamagishi S, Fujita Y, Hoshina D, Sasaki M, Nakamura K, Matsui T, Shimizu T, Bucala R, Shimizu H. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J Dermatol Sci. 2010 Mar;57(3):183-91. doi: 10.1016/j.jdermsci.2009.12.010. Epub 2010 Jan 8.</citation>
    <PMID>20060688</PMID>
  </results_reference>
  <results_reference>
    <citation>Pyla R, Poulose N, Jun JY, Segar L. Expression of conventional and novel glucose transporters, GLUT1, -9, -10, and -12, in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2013 Mar;304(6):C574-89. doi: 10.1152/ajpcell.00275.2012. Epub 2013 Jan 9.</citation>
    <PMID>23302780</PMID>
  </results_reference>
  <results_reference>
    <citation>Shurman DL, Glazewski L, Gumpert A, Zieske JD, Richard G. In vivo and in vitro expression of connexins in the human corneal epithelium. Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1957-65.</citation>
    <PMID>15914609</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>SSElkady</investigator_full_name>
    <investigator_title>Demonstrator at Medical Biochemistry department</investigator_title>
  </responsible_party>
  <keyword>GLUT 1</keyword>
  <keyword>PEDF</keyword>
  <keyword>Psoriasis Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

